Why the study?
Does warfarin sodium improve the promptness and maintenance of desired prothrombin levels compared to bishydroxycoumarin in patients requiring anticoagulant therapy?
Does warfarin sodium improve the promptness and maintenance of desired prothrombin levels compared to bishydroxycoumarin in patients requiring anticoagulant therapy?
Warfarin sodium is superior to bishydroxycoumarin in rapidly achieving and reliably maintaining target prothrombin levels with a similar or slightly lower risk of hemorrhagic side effects.
Answers are grounded in this paper and cite their sources.
Warfarin may achieve faster, more stable prothrombin control than bishydroxycoumarin; this Level 3 cohort finding leaves open the need for randomized outcome trials.
Coumadin sodium and bishydroxycoumarin were used in a study of the effects of anticoagulant therapy on 200 patients, most of them with acute myocardial infarction or severe coronary insufficiency. Coumadin sodium was given orally to 164 of these patients, the prothrombin times being determined daily. Individual dosages were adjusted until the daily dose (usually 5 to 7.5 mg.) needed to maintain the prothrombin level between 15 % and 30% was found. Bishydroxycoumarin was given to 19 patients and dosages were similarly adjusted until the maintenance dose (between 20 and 100 mg. daily) was found. An additional group of 17 patients who at first received bishydroxycoumarin were shifted to therapy with coumadin sodium. Coumadin sodium was found to be far superior to bishydroxycoumarin. Coumadin sodium had the advantage of greater promptness of effect; it produced the desired prothrombin levels within 48 hours in 87% of the cases. Patients receiving it in maintenance doses were more likely to stay within the desired range of prothrombin levels. The frequency of side-effects (mainly hemorrhagic) was slightly though not significantly lower in the patients treated with coumadin sodium. Nine patients who exhibited bleeding phenomena promptly responded to withdrawal of the coumadin sodium or treatment with preparations of vitamin K.
No takes yet. Share an insight, caveat, or question.
Samuel Baer (1958) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: